Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143229 · ClinicalTrials.gov registry record · Phase 1
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT05143229 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 18 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05143229, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
- DRUG Alpelisib
Study Locations (7)
Kansas
- The University of Kansas Clinical Research Center - Fairway
- The University of Kansas Cancer Center - Overland Park - Overland Park
- The University of Kansas Cancer Center - Indian Creek - Overland Park
- The University of Kansas Cancer Center - Westwood
Missouri
- The University of Kansas Cancer Center - North Kansas City Hospital - Kansas City
- The University of Kansas Cancer Center - North - Kansas City
- The University of Kansas Cancer Center - Lee's Summit - Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05143229
The ClinicalTrials.gov registry entry for NCT05143229 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sacituzumab govitecan is the first listed.
NCT05143229 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT05143229 about?
NCT05143229 is a clinical study titled "Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer". This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
What is the current status of trial NCT05143229?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-03-28. Estimated completion is 2025-12.
What conditions does trial NCT05143229 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05143229?
The interventions under investigation include: Sacituzumab govitecan (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT05143229?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143229 being conducted?
This trial has 7 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.